Pleiotropic effects of statins and their clinical significance

American Journal of Cardiology

Volumn 88, Issue 3, 2001, Pages 291-293

  LaRosa, John C ^a  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; C REACTIVE PROTEIN; CHOLESTEROL; LOW DENSITY LIPOPROTEIN; MEDROXYPROGESTERONE; NITRIC OXIDE; PRAVASTATIN; STATIN;

ARTICLE; ATHEROGENESIS; ATHEROMA; ATHEROSCLEROSIS; BLOOD VESSEL REACTIVITY; CELL ACTIVITY; CELL ADHESION; CHOLESTEROL BLOOD LEVEL; CHRONIC INFLAMMATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; ENDOCYTOSIS; ENDOTHELIUM CELL; HEART MUSCLE CELL; HUMAN; LIPOPROTEIN BLOOD LEVEL; LYSIS; MACROPHAGE; OXIDATION; PATHOPHYSIOLOGY; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR; STROKE; THROMBOSIS;

EID: 0035422745     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(01)01643-5     Document Type: Note

References (24)

1. Effects of statins on risk of coronary disease. A meta-analysis of randomized controlled trials
2. Lipids and the endothelium
3. Do pleiotropic effects of statins beyond lipid alterations exist in vivo? What are they and how do they differ between statins?
4. Antiatherothrombotic properties of statins. Implications for cardiovascular event reduction
5. Low-density lipoprotein-independent effects of statins
6. Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys
7. The effect of simvastatin treatment on natural antioxidants in low-density lipoproteins and high-energy phosphates and ubiquinone in skeletal muscle
8. Requirement for mevalonate in acetylated LDL induction of cholesterol esterification in macrophages
9. Methods and endpoint issues in clinical development of lipid-acting agents with pleiotropic effects
10. Effect of pravastatin on outcomes after cardiac transplantation
11. Long-term effects of pravastatin on plasma concentration of C-reactive protein
12. Direct vascular effects of HMG-CoA reductase inhibitors
13. Influences of lipid-modifying agents on hemostasis
14. Vastatins inhibit tissue factor in cultured human macrophages
15. Anticoagulant activity of tissue factor pathway inhibitor in human plasma is preferentially associated with dense subspecies of LDL and HDL and with Lp(a)
16. Treatment with hydroxymethyl-glutaryl-coenzyme A reductase inhibitors in hypercholesterolemia induces changes in the components of the extrinsic coagulation system
17. Cholesterol, stroke risk, and stroke prevention
18. Relationship between LDL-C changes and CHD event reduction with pravastatin in the West of Scotland Coronary Prevention Study (WOSCOPS)
19. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels
20. Hydroxymethylglutaryl coenzyme. A reductase inhibitors modify the inflammatory response of human macrophages and endothelial cells infected with chlamydia pneumoniae
21. Ubiquinone supplementation during lovastatin treatment: Effect on LDL oxidation ex vivo
22. Women, dyslipoproteinemia, and estrogens
23. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women
24. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis